km.idaeo.ai · IDAEO 知識庫

🏛 本文属于主题馆「reports」 →

牙科麻醉、镇静与看牙恐惧全指南：从局部麻醉原理、镇静光谱到焦虑评估的领域地图｜證據鏈

km 編輯部2026-08-13阅读约 77 分钟
#證據鏈#牙醫領域#麻醉#兒童

本頁是〈牙科麻醉、镇静与看牙恐惧全指南：从局部麻醉原理、镇静光谱到焦虑评估的领域地图〉的事實單元帳：每一條主張對應的來源、證據等級、地域與期間、原文引句與限制，逐條攤開。

牙科麻醉、镇静与看牙恐惧全指南：从局部麻醉原理、镇静光谱到焦虑评估的领域地图｜證據鏈

F-Units（事实单元帐）

展开 F1–F30 事实帐（每条：来源#／confidence／basis／geo／period／caveat）

F1｜麻醉的四类官方分类（局部／区域／全身／监测型镇静）与镇静的三个深度层级（轻度／中度即清醒镇静／深度）；镇静不同于完整麻醉，不使人完全失去意识且恢复较快；监测型镇静明列可用于牙科治疗

  • 对应 Fn: Fn1, Fn3, Fn4, Fn5, Fn6, Fn11, Fn12, Fn13, Fn14, Fn15, Fn16, Fn17, Fn18
  • 来源#: #S01｜confidence: high｜basis: official_statement（美国 NIH／NLM MedlinePlus 卫教页，2026-08-06 实测 HTTP 200，90,744 bytes）｜geo: universal｜period: 2026-08-06 取用之页面版本
  • caveat: 属病人卫教层级之定义叙述，非临床操作准则；本文仅用其名词分类，不用其作任何效果或安全性宣称。依「全线 global」修订，本条为美国联邦机构之普世卫教内容（不含美国专属制度性宣称），故 geo 标 universal。该页列的是三个离散层级（Minimal／Moderate (conscious)／Deep），原文未出现「连续光谱（continuum）」措辞，亦无「牙科镇静」之限定主词——2026-08-06 修正回合已把 TL;DR 由「牙科镇静是一条由浅到深的连续光谱而非单一开关 [Fn1]」改为与原文对得上的「镇静分轻度、中度、深度三个层级，与完整麻醉不同 [Fn1]」，1-1 节可携的读法与 FAQ Q3 首句之同一措辞亦一并改为分层叙述；「光谱」一词仅保留于第四节标题等纯编辑性框架处，不挂 [Fn]、不作事实宣称。

F2｜麻醉整体上安全但有风险（尤以全身麻醉）；官方列出之风险含心律不整、呼吸问题、对麻醉药之过敏反应、暂时性意识混乱（部分 60 岁以上者可持续数日、儿童苏醒后短暂）、全身麻醉下之知觉（通常为听到声音、偶有疼痛，属罕见）；建议与医疗提供者讨论益处与风险

  • 对应 Fn: Fn101, Fn102, Fn103, Fn104, Fn105, Fn106, Fn107
  • 来源#: #S01｜confidence: high｜basis: official_statement｜geo: universal｜period: 2026-08-06 取用之页面版本
  • caveat: 为风险「清单」而非发生率；该页未提供各项之量化频率，本文未对其作任何概率陈述。

F3｜牙科治疗疼痛为病人常见恐惧，可由局部麻醉成功控制；Cochrane 纳入 123 篇研究、19,223 名受试者，涵盖 14 种不同配方，并比较出配方间之麻醉成功率差异；不良事件罕见

  • 对应 Fn: Fn22, Fn23, Fn24, Fn31, Fn34
  • 来源#: #S04｜confidence: high｜basis: peer_reviewed（Cochrane 系统综述与荟萃分析，PMID 29990391）｜geo: universal｜period: Cochrane Database Syst Rev, 2018（检索至 2018-01-31）
  • caveat: 该回顾多数结果之质量评为低至中等；其成功率比较之具体药剂组合本文未逐一转述（属用药层级）。另有 34 篇「待分类（全文无法取得）」研究，作者自陈其评估后可能改变结论。

F4｜Cochrane 主要目标包含比较起效速度与持续时间，但对于评估起效与持续时间之比较，没有临床研究符合其结果定义

  • 对应 Fn: Fn32, Fn33
  • 来源#: #S04｜confidence: high｜basis: peer_reviewed（PMID 29990391）｜geo: universal｜period: Cochrane Database Syst Rev, 2018
  • caveat: 本条为证据缺口之陈述，不是效果陈述。 锚定档 P21-anchors.md 将 #05 标为「麻药多久退」之核心锚并描述其「以持续时间为比较目标」，该描述仅涵盖 Objectives 段而未涵盖 Main results 段之否定结果；本文以原文结果段为准（见「编辑裁定与锚定档修正记录」第 2 条）。

F5｜电脑控制局部麻醉输注系统（CCLAD）于 3–14 岁儿童显著降低注射疼痛感受：Wong-Baker 量表 SMD = -0.98（p = 0.011）、心率 SMD = -0.25（p = 0.013）；次人群分析中相较传统 IANB 具显著降低；异质性分别为高与中等；其他量表与注射方式之结果不一、出现部分不具显著性之差异；其他疼痛评估参数未观察到显著差异；仅 5 篇为低偏倚风险、证据确定性介于极低至中等；作者结论用语为 CCLAD「展现出潜力（demonstrates potential）」

  • 对应 Fn: Fn25, Fn26, Fn27, Fn28, Fn29, Fn139, Fn140, Fn141
  • 来源#: #S03｜confidence: moderate｜basis: peer_reviewed（20 篇 RCT 之系统综述与荟萃分析，PMID 40254248）｜geo: universal｜period: J Dent, 2025（纳入 2015-01 至 2024-11 发表之 RCT）
  • caveat: 人群限定为 3–14 岁儿童，禁外推为成人效果。 原文之两句反向限制（其他量表／注射方式部分无显著差异、其他疼痛评估参数无显著差异）已于 2026-08-06 修正回合自 caveat 提升至正文与 FAQ [Fn139][Fn140]；作者结论用语为 potential（潜力）而非确立效果，本文小标与 FAQ 首答已同步降阶 [Fn141]。本条为器材层级之人群结果，不构成任何器材推荐。

F6｜4% articaine 与 2% lidocaine 之注射后疼痛差异很小；lidocaine 可能造成略少之注射后疼痛（中等质量证据）

  • 对应 Fn: Fn30
  • 来源#: #S04｜confidence: moderate｜basis: peer_reviewed（PMID 29990391）｜geo: universal｜period: Cochrane Database Syst Rev, 2018
  • caveat: 原文以 170 mm Heft-Parker 视觉类比量表测量之连续变项；本文未转述其毫米数值与剂量信息。不构成用药指示。

F7｜儿童局部麻醉后之自伤性软组织创伤：574 篇筛选出 21 篇（9 RCT／6 病例报告／6 世代），人群以 6–12 岁为主；可造成显著疼痛与合作问题；有效策略含及早之药物与非药物介入；整理到之介入含酚妥拉明（2 篇）、口内装置（2 篇）、光生物调节（2 篇）

  • 对应 Fn: Fn35, Fn36, Fn37, Fn38, Fn39, Fn40, Fn41
  • 来源#: #S05｜confidence: moderate｜basis: peer_reviewed（系统综述，PMID 40856087）｜geo: universal｜period: Adv Clin Exp Med, 2026（检索至 2024-10）
  • caveat: 作者自陈纳入研究在设计、样本量与时程上差异很大，效应量与置信区间报告不一致，并有方法学异质与潜在报告偏倚。本文未转述任何药物之剂量、途径或时机。

F8｜对局部麻醉之不良反应通常为肾上腺素反应、血管迷走性昏厥或过量毒性；具真过敏者有时于全身麻醉下接受治疗

  • 对应 Fn: Fn42, Fn72
  • 来源#: #W22｜confidence: moderate｜basis: peer_reviewed（回顾含病例报告，PMID 29952645）｜geo: universal｜period: Anesth Prog, 2018
  • caveat: 本篇 PublicationType 含 Case Reports，证据层级低于系统综述；本文仅用其鉴别分类之方向陈述，未引用其病例之任何处置细节或替代药物用法。

F9｜局部麻醉全身性毒性（LAST）为罕见但可能致命之并发症；不同指引来源对用量上限之建议存在临床上显著分歧；合并使用多种醯胺类药剂之加成毒性被低估；静脉脂肪乳剂为严重／心血管型 LAST 之特定救援疗法，气道支持与氧合仍为优先介入；病人个别因素显著拉低有效毒性阈值；需结构化鉴别诊断以与较常见之牙科急症区分

  • 对应 Fn: Fn44, Fn45, Fn46, Fn47, Fn48, Fn49
  • 来源#: #S12｜confidence: moderate｜basis: peer_reviewed（叙述性回顾，PMID 42505765）｜geo: universal｜period: Dent J (Basel), 2026（检索至 2026-05）
  • caveat: 属叙述性回顾（narrative review），非系统综述；原文明示其来源阶梯为英国处方与法规脉络专属（UK-specific hierarchy），本文因此只取其普世性之机制与流程陈述，不取其任何剂量数值、不取其国别法规建议。本条不构成用药指示。

F10｜牙科临床过敏反应之三类机制：IgE 媒介之立即型、致敏 T 淋巴球媒介之延迟型、假过敏反应；交叉反应之重要性；诱因含局部麻醉药（lidocaine、benzocaine）、抗生素（青霉素、头孢菌素）、乳胶（手套、橡皮障）、压克力材料、含镍／铬／钴之金属合金

  • 对应 Fn: Fn50, Fn51, Fn52, Fn53, Fn54, Fn55
  • 来源#: #S11｜confidence: high｜basis: peer_reviewed（系统综述，PMID 39954171）｜geo: universal｜period: Clin Rev Allergy Immunol, 2025
  • caveat: 摘要未提供各诱因之发生率，本文仅用其分类与清单，未作任何频率陈述。

F11｜涉及 IgE 媒介与过敏性休克之真正局部麻醉药过敏罕见，仅于病例报告中被辨识，占局部麻醉药不良反应不到 1%；多数反应为非过敏性，或属对防腐剂、赋形剂等其他来源之过敏；误分类可导致不必要地回避局部麻醉药或延误手术

  • 对应 Fn: Fn2, Fn56, Fn57, Fn62
  • 来源#: #W17｜confidence: high｜basis: peer_reviewed（回顾，PMID 35482282）｜geo: universal｜period: Clin Rev Allergy Immunol, 2023
  • caveat: 「不到 1%」为回顾之整体性表述，原文未附该比例之统合计算过程；本文仅用其量级，不作精确推论。限定不可脱落：原文之 <1% 明白限定于「涉及 IgE 媒介与过敏性休克（involving IgE-mediated reactions and anaphylaxis）」之真过敏，不涵盖延迟型（type IV）真过敏（F12 之 articaine 25 年盘点中即有 5 例 type IV 确认病例）——2026-08-06 修正回合已把此限定补回 TL;DR 与第七节副作用清单两处（原本仅 3-2 节与 FAQ Q4 保留），全文四处措辞现已一致。

F12｜articaine 真过敏之 25 年盘点（2000-01 至 2024-12）：10 篇病例报告与 6 篇病例系列、合计 29 名经标准过敏学程序确认之病人；20 名为立即型（type I）、5 名为延迟型（type IV）；与其他醯胺类之交叉反应报告于 3 例；作者结论为真过敏极为罕见

  • 对应 Fn: Fn58, Fn59, Fn60, Fn61
  • 来源#: #W18｜confidence: moderate｜basis: peer_reviewed（回顾，PMID 40422600）｜geo: universal｜period: Dent J (Basel), 2025
  • caveat: 设计为文献中已发表病例之汇整，依赖通报，只能证明「经确认之案例极少」，不等于已测得人群发生率；4 例未载明过敏型别。本条仅涵盖 articaine 一种药物。

F13｜疑似局部麻醉药过敏之标准化诊断结果：单一过敏中心 24 名转诊病例中，经标准化皮肤测试与药物激发测试后 3 例被认定为过敏；3 例（12.5%）过去皮试阳性者经标准化流程排除；其余归为心身反应 29.1%、交感神经刺激症状 12.5%、血管迷走性昏厥 8.3% 等；结论为真过敏罕见、绝大多数自述者可被排除

  • 对应 Fn: Fn43, Fn63, Fn64, Fn65, Fn66
  • 来源#: #W21｜confidence: low（各百分比）／moderate（方向与流程）｜basis: peer_reviewed（回顾性系列，PMID 38186148）｜geo: universal｜period: 2017-03 至 2022-02 收案
  • caveat: 单一医学中心、仅 24 人、回顾性设计、性别分布高度不均（3 男／21 女）；百分比之分母极小，本文仅用其方向与流程，禁作人群推论。

F14｜诊断路径：详细之过去反应病史为起手且关键之步骤；疑似立即型过敏可用皮肤点刺与皮内测试加后续分级激发评估；疑似延迟型可用贴肤测试评估

  • 对应 Fn: Fn67, Fn68, Fn69
  • 来源#: #W17｜confidence: high｜basis: peer_reviewed（PMID 35482282）｜geo: universal｜period: Clin Rev Allergy Immunol, 2023
  • caveat: 为流程层级陈述，未载各测试之敏感度／特异度；本文不建议任何人自行安排检测。

F15｜确诊醯胺类过敏者之替代方向：氯普鲁卡因（酯类麻醉剂）被建议用于已确诊醯胺类过敏之病人；局部麻醉药之选择必须依每位病人之医疗状况量身决定

  • 对应 Fn: Fn70, Fn71
  • 来源#: #S13｜confidence: moderate｜basis: peer_reviewed（综合性回顾，PMID 41710613）｜geo: universal｜period: Saudi J Anaesth, 2026（检索 2000-01 至 2025-04）
  • caveat: 属回顾之临床建议整理，非原始比较试验；本文未转述其对各系统性疾病之个别药物偏好细节与任何剂量。不构成用药指示。 原文只点名单一药物（Chloroprocaine），未建议整个酯类药物家族——2026-08-06 修正回合已把第七节禁忌证与 FAQ Q4 之「改用酯类药物」概括改回点名氯普鲁卡因，并注明同属酯类的 benzocaine 在 #S11 中被列为牙科过敏诱因之一 [Fn54]，故禁作药类层级之推广。

F16｜笑气（N₂O/O₂）于 2–12 岁儿童之表现：轻度焦虑效果 85–92%、并发症低于 5%（如恶心）、起效 30–60 秒、五分钟内完全恢复，适用短时程处置；整体不良事件低于 5%，笑气于门诊使用相对更安全；系统综述纳入 25 篇研究、约 12,500 名受试者

  • 对应 Fn: Fn19, Fn73, Fn78, Fn79, Fn80, Fn81
  • 来源#: #S08｜confidence: low-moderate｜basis: peer_reviewed（系统综述，PMID 41694161）｜geo: universal｜period: Cureus, 2026（检索 2015–2025）
  • caveat: 85–92% 对应「轻度焦虑」次人群，禁套用于中重度焦虑者；人群为 2–12 岁儿童，禁外推成人。 该回顾因异质性采质性综合而非荟萃分析，作者自陈限制含协议变异与 RCT 数量有限；纳入设计混合 RCT、世代与回顾。

F17｜口服镇静于 2–12 岁儿童之表现：中度病例成功率 70–85%；midazolam 提供较强失忆效果但有 5–10% 矛盾兴奋；hydroxyzine 适合作为低风险辅助；合并使用可提升至 88–95% 并使中断率减少 40–50%

  • 对应 Fn: Fn74, Fn82, Fn83, Fn84
  • 来源#: #S08｜confidence: low-moderate｜basis: peer_reviewed（PMID 41694161）｜geo: universal｜period: Cureus, 2026
  • caveat: 同 F16 之人群与方法限制。药名为文献转述，本文不提供任何剂量、途径或给药时机，亦不构成用药指示。

F18｜种植牙手术之静脉镇静 RCT：255 名连续种植牙病患随机分为静脉镇静合并局麻组（n=123）与纯局麻组（n=132）；收缩压与／或舒张压在非镇静组显著较高；结果段载该方案稳定血液动力学并有助于病人安全；结论段之表述较窄，仅载静脉镇静对种植牙手术中之血液动力学变化有正面效果

  • 对应 Fn: Fn75, Fn85, Fn86, Fn87, Fn142
  • 来源#: #S06｜confidence: moderate｜basis: peer_reviewed（随机对照试验，PMID 22167437）｜geo: universal｜period: Int J Oral Maxillofac Implants, 2011
  • caveat: 结果变项为血液动力学指标，非并发症率或存活率；为 2011 年之单一 RCT，本轮未检得等效之后续荟萃分析。「有助于病人安全」（contributed to the safety of the patient）一语位于原文 RESULTS 段，不在 CONCLUSION 段——2026-08-06 修正回合已将正文「作者的结论写着」改为「结果段写着」，并补上结论段的较窄表述 [Fn142]；此为与本文 4-7 节同一标准之一致适用（禁把非结论段句子当作者结论）。不得改写为任何安全性保障。所用药物组合本文未转述剂量。

F19｜连续输注镇静后之恢复时间：ASA 分级 I 或 II 之病人、46 人之前瞻性观察研究，以双频谱指数与麻醉后出院评分系统量化；原文结论带条件前提——「若约 50 分钟之 midazolam 清醒镇静获得妥善控制，病人可于自开始给药起『约』90–110 分钟内出院」，即清醒后约 40–60 分钟内返家；排除未满 18 岁、药物过敏史、BMI 26 以上、规律使用抗精神病／精神作用／安眠物质者

  • 对应 Fn: Fn20, Fn88, Fn89, Fn90, Fn91, Fn92
  • 来源#: #S07｜confidence: low-moderate｜basis: peer_reviewed（前瞻性观察研究，PMID 41717147）｜geo: universal｜period: Cureus, 2026（2019-12 至 2021-07 於单一大学附属医院收案）
  • caveat: 单一机构、46 人、观察性设计（非 RCT）；排除条件广，时间数字禁套用于被排除人群。该时间区间绑定的是该研究约 50 分钟之镇静时长，且原文用语为「约（approximately）」——2026-08-06 修正回合已把条件从句与「约」字补回 4-4 节与 4-8 节，禁再写成无条件之固定区间，亦禁读成「任何长度的舒眠处置都是 90–110 分钟」。本文未转述其任何给药剂量或输注参数。

F20｜全身麻醉于特殊照护牙科（成人服务）之指引定位：可能被需要以支持照护，理由含让有重度学习障碍或重度看牙恐惧者接受广泛牙科治疗；因涉潜在风险、影响与成本而需要指引；以总则加六个关键章节呈现，涵盖自转诊至术后之病人路径；强调全面且以人为中心之评估与计划；指引自陈可用证据很少，建议主要基于工作小组专家共识

  • 对应 Fn: Fn21, Fn77, Fn93, Fn94, Fn95
  • 来源#: #S02｜confidence: high（框架）／low（效果面）｜basis: clinical_guideline（英国身心障碍牙科学会临床指引，PMID 35061301；PublicationType 含 Practice Guideline）｜geo: universal｜period: Spec Care Dentist, 2022
  • caveat: 原文明示「证据很少，建议主要基于专家共识」，本条仅可作决策框架，不得作效果或安全性证据。指引之适用对象为特殊照护牙科（SCD）服务中之成人（原文 AIM: for adults within SCD services），外推至一般成人牙科人群属本文未主张之范围——2026-08-06 修正回合已把此服务情境补回 5-4 表、FAQ Q3、第七节适应证与第八节导言四处，禁再写成「指引承认全身麻醉可用于重度看牙恐惧」之无情境通则。

F21｜儿童全身麻醉下口腔手术之术后病症：适应证占比居前者为龋齿及其并发症（达 91.0%），其次为缺乏合作／焦虑／恐惧（39.8–47.9%）；特殊需求人群处置比例 87.7%、健康病人 63.3%；43.0–98.9% 于头 24 小时内出现不适，主因为疼痛（14.0–95.0%）；结论为重大并发症风险很低但轻微并发症几乎普遍发生

  • 对应 Fn: Fn76, Fn96, Fn97, Fn98, Fn99, Fn100
  • 来源#: #S14｜confidence: moderate｜basis: peer_reviewed（系统综述，PMID 35961509）｜geo: universal｜period: J Stomatol Oral Maxillofac Surg, 2023（检索至 2022-02-23）
  • caveat: 各区间跨度极大（如疼痛 14.0–95.0%），反映纳入研究之测量方式与定义差异，禁取中点或作个别预测；人群为儿童，禁外推成人。原文亦载无法建立共病与所执行处置之关联。

F22｜十二部国际儿童牙科清醒镇静指引之比较：核心安全领域（病人评估、监测、专业人员训练）呈完全一致；出院标准一致性 91.67%、禁忌证 83.33%；药理协议变异实质，仅 16.67% 提供完整药物与剂量描述；给药途径与急救设备分别出现于 66.67% 与 50%；结论为基础安全原则一致但药理与程序建议显著异质，此变异可能导致实务差异与执业者不确定

  • 对应 Fn: Fn108, Fn109, Fn110, Fn111, Fn112, Fn113
  • 来源#: #S09｜confidence: high｜basis: peer_reviewed（指引比较分析与证据地图研究，PMID 41976973）｜geo: universal｜period: J Clin Med, 2026（检索至 2023-12）
  • caveat: 本篇为指引之比较研究，非指引本身；所比较之十二部指引其发布机构与年份未于摘要逐一列出，本文未逐一引述其个别内容。一致性百分比描述的是「指引之间是否涵盖该领域」，不是临床效果。主题与人群限定：原文标题与纳入条件均为「儿童牙科（pediatric dentistry）之清醒镇静（conscious sedation）」指引，不涵盖成人镇静，亦不涵盖全身麻醉——2026-08-06 修正回合已把此限定补进 4-6 节（含节标题）、4-8 节、第六节人群清单、第七节禁忌证与第八节提问清单全部引用处，禁再以「十二部国际指引」之无限定写法出现，亦禁把任何一致性百分比外推为成人或全身麻醉之指引共识。

F23｜镇静与全身麻醉用于未满 18 岁牙科治疗之比较：Cochrane 原始回顾筛出 16 篇可能纳入者，取全文后无一符合资格；2012 年更新未增；2015 年更新找到 2 篇亦不符资格；作者结论为需要随机对照研究以量化病症与成本差异

  • 对应 Fn: Fn114, Fn116, Fn117, Fn118
  • 来源#: #S15｜confidence: high｜basis: peer_reviewed（Cochrane 系统综述，PMID 26413895）｜geo: universal｜period: Cochrane Database Syst Rev, 2015（2009 年初版，2012／2015 更新）
  • caveat: 本条为「空回顾」（无合格纳入研究），是证据缺口之陈述，不是任一方之效果证据。 人群限定：原文标题为 patients younger than 18 years、纳入条件为 children and adolescents up to 18 years of age——2026-08-06 修正回合已把此年龄限定补回 4-7 节结论句与节标题、5-4 表第三列与表后结语、FAQ Q3，禁再写成「镇静与全身麻醉之间并无头对头实证比较」之通则；成人人群不在该回顾检索范围内，故本空回顾既不能证明成人有此类证据，也不能证明成人没有。

F24｜「镇静可能导致较低之病症与成本」一语出自该 Cochrane 回顾之背景段（历史脉络与研究动机），非其研究发现

  • 对应 Fn: Fn115
  • 来源#: #S15｜confidence: high｜basis: peer_reviewed（PMID 26413895）｜geo: universal｜period: Cochrane Database Syst Rev, 2015
  • caveat: 本条为引用位置之更正记录。 锚定档 P21-anchors.md 将 #16 描述为「明确指出使用镇静可能降低病症发生率与成本」，该句实际位于 BACKGROUND 段且为条件语气（may lead to），与 Main results 之否定结果并列时不可读为结论（见「编辑裁定与锚定档修正记录」第 3 条）。

F25｜成人牙科恐惧与焦虑之全球估计患病率：31 篇人群为本研究、72,577 名 18 岁以上成人；DFA 15.3%（95%CI 10.2–21.2）、高度 DFA 12.4%（95%CI 9.5–15.6）、严重 DFA 3.3%（95%CI 0.9–7.1）；女性与较年轻成人较高；31 篇中 28 篇为高偏倚风险；测量工具会影响所测得之患病率

  • 对应 Fn: Fn7, Fn8, Fn9, Fn10, Fn119, Fn120
  • 来源#: #W16｜confidence: moderate｜basis: peer_reviewed（系统综述与荟萃分析，PMID 33711405）｜geo: universal｜period: J Dent, 2021（检索至 2020-03）
  • caveat: 28/31 篇为高偏倚风险、仅 3 篇低偏倚风险；置信区间宽（DFA 10.2–21.2）；作者自陈测量工具影响患病率，故各数字不得跨量表互比。15.3%／12.4%／3.3% 为三组各自合并估计之结果，非同一样本之巢状分层——2026-08-06 修正回合已删除 5-1 节「两者相差约 12 个百分点」之自行相减推导（原文未授权此运算），改为三数并列并注明不得相减。

F26｜牙科焦虑之评估以经验证量表为门槛：系统综述之纳入条件指名牙科焦虑量表（DAS）与牙科恐惧调查（DFS），或符合牙科恐惧症之精神科诊断标准

  • 对应 Fn: Fn121
  • 来源#: #S10｜confidence: high｜basis: peer_reviewed（系统综述，PMID 23659254）｜geo: universal｜period: Eur J Oral Sci, 2013
  • caveat: 为纳入准则之陈述，非量表效度之评比；本文未主张任一量表较佳。

F27｜修正版牙科焦虑量表（MDAS）之形式与信度：五个题目、总分 5 至 25；于 230 名口腔外科病人之版本验证中内部一致性高（Cronbach's alpha = 0.92）；分数在女性与过去有医疗／牙科痛苦经验者显著较高；与年龄及看牙频率之相关亦达显著

  • 对应 Fn: Fn122, Fn123, Fn124, Fn125, Fn126, Fn127
  • 来源#: #W20｜confidence: moderate（形式与信度）／low（任一数值之外推）｜basis: peer_reviewed（量表验证研究，PMID 26173721）｜geo: universal｜period: Minerva Stomatol, 2015
  • caveat: 为单一语言版本之验证研究，且受试者限于口腔外科人群；作者自陈此为限制，可能无法代表一般牙科人群之焦虑患病率。本文仅用其说明工具形式与信度量级。

F28｜成人牙科焦虑之心理处置：10 篇 RCT 之系统综述；CBT/BT 带来显著之焦虑降低（DAS 平均差 -2.7），惟建立于低质量证据；另有部分支持显示 CBT/BT 在改善治疗接受度上优于全身麻醉（低质量证据）；总结为行为介入可帮助成人但需更多良好设计研究

  • 对应 Fn: Fn128, Fn129, Fn130, Fn131, Fn132
  • 来源#: #S10｜confidence: low-moderate｜basis: peer_reviewed（系统综述，PMID 23659254）｜geo: universal｜period: Eur J Oral Sci, 2013
  • caveat: 作者两度标示低质量证据；仅 10 篇 RCT；发表年代较早（2013），本轮未以更新版本取代（见自查节）。不得改写为「已证实有效」。

F29｜降低成人牙科焦虑之临床试验回顾（原文标题与主轴为「催眠对牙科焦虑与恐惧症之疗效」）：19 篇临床试验（1979–2021），涵盖各形式 CBT、放松训练、苯二氮平类前用药、自我催眠音档、催眠治疗与笑气镇静；以各种形式提供之 CBT（含单次治疗）显示降低焦虑之证据支持程度居前；因方法高度异质仅 5 篇进入荟萃分析，催眠之应用呈现彼此矛盾之结果；作者同时表述系统综述结果具前景、催眠亦可被视为降低焦虑之有力而成功之方法，惟亦有效果很小甚至略为负向之研究；建议催眠研究需更一致之焦虑测量方法

  • 对应 Fn: Fn133, Fn134, Fn135, Fn136, Fn137, Fn138
  • 来源#: #W19｜confidence: low-moderate｜basis: peer_reviewed（系统综述与荟萃分析，PMID 35624907）｜geo: universal｜period: Brain Sci, 2022（纳入 1979–2021 发表之试验）
  • caveat: 仅 5 篇进入荟萃分析、催眠结果矛盾；药物项（苯二氮平类前用药）仅为所检视处置之列举，本文未引用其任何效果数字，亦不构成用药指示。来源定位揭露：本文用它支撑 CBT 的比较性表述，但它是一份以催眠为主题的回顾——2026-08-06 修正回合已于 5-3 节正文明白揭露其标题主轴 [Fn133]，并补上作者对催眠的正面表述 [Fn138]，以免形成只取对催眠不利一侧的选择性引用。

F30｜镇静与全身麻醉之费用组成变因（人员训练、监测、急救设备、恢复时间、处置范围）可由指引涵盖领域与观察研究之恢复时间推得；专业指引亦明白将成本与风险、影响并列为需要指引之理由

  • 对应 Fn: 本节所引 Fn108, Fn109, Fn112, Fn90, Fn93, Fn94, Fn4, Fn5, Fn6（无独立新事实）
  • 来源#: #S09／#S07／#S02｜confidence: moderate（组成逻辑）｜basis: clinical_guideline／peer_reviewed｜geo: universal｜period: 见各对应条
  • caveat: 本条仅为费用「组成与变因」之推导，不含任何金额、不含任何国别给付规则；各国制度差异详见领域文 P12 与对应 TW 正典卡。#S09 之涵盖范围限于儿童牙科清醒镇静指引 [Fn108]——2026-08-06 修正回合已删除 4-8 节「代表镇静与全身麻醉需要具备对应训练的人力在场」之跨处置外推（该研究不比较全身麻醉指引），改为清醒镇静侧挂 #S09、全身麻醉侧挂 #S02 之 Fn94；同节「深度愈深，监测需求愈高」之无源因果句亦一并删除，改为「这次做的是哪一段、监测怎么安排是可向医师确认的事项」之提问导引。

合规注记

  • 本文为医学卫生教育与医学新知性质之领域说明，目的在于协助读者理解牙科麻醉与镇静的分类、证据强度与提问方向，未涉及招徕就医，亦不含任何医疗机构、人员或服务之推介。
  • 全文不报实价、不列金额、不含任何价格诱因；费用段落仅说明组成与变因。
  • 全文不提供任何用药剂量、给药途径、给药时机或停药建议；文中出现之药物名称仅为所引文献之名词转述，不构成用药指示，亦不涉及任何产品或器材之推荐。
  • 全文未使用疗效承诺、绝对化或夸大比较性措辞，未含病患经验陈述或可识别之个案。
  • 提及各项处置处均已揭露适应证、可能之副作用与禁忌证（见第七节）；此一揭露依国际文献与专业指引之记载呈现，本文不以任何特定国家之法规作为其规范依据（本篇 geo_scope 为 global，在地法规要求详见对应 TW 正典卡）。
  • 实际治疗方式与效果因人而异，须由牙医师评估。 是否适合任何一种麻醉或镇静方式、采用何种深度、需要哪些术前检查，一律须经合格牙医师（必要时会同麻醉专业）当面评估。
  • 本文所引数字多有明确之人群限定（儿童／特定 ASA 分级／特定焦虑程度），已于各段逐条标示；读者不应将其套用于自身。
  • ⚠ 本文为 draft，尚未经机器闸门、跨架构对抗审与主帅亲验，禁止发布。

来源清单

取用／实测日期：2026-08-06（全部来源同日以 curl／PubMed E-utilities 实测，HTTP 200，逐字 span 以程式比对通过）

锚定档既验来源（`ida-pillars/anchors/P21-anchors.md`）

#basis标题出处PMID／URL
#S01official_statementAnesthesia（MedlinePlus Health Topic）U.S. National Library of Medicine（NIH）https://medlineplus.gov/anesthesia.html
#S02clinical_guidelineThe use of general anaesthesia in special care dentistry: A clinical guideline from the British Society for Disability and Oral Health.Spec Care Dentist, 2022（PublicationType: Practice Guideline）PMID 35061301｜https://pubmed.ncbi.nlm.nih.gov/35061301/
#S03peer_reviewedComparison of injection pain levels using conventional and computer-controlled local anesthetic delivery systems in pediatric dentistry: A systematic review and meta-analysis.J Dent, 2025PMID 40254248｜https://pubmed.ncbi.nlm.nih.gov/40254248/
#S04peer_reviewedInjectable local anaesthetic agents for dental anaesthesia.Cochrane Database Syst Rev, 2018PMID 29990391｜https://pubmed.ncbi.nlm.nih.gov/29990391/
#S05peer_reviewedDiagnosis and management of traumatic injuries in pediatric patients secondary to dental local anesthesia: A systematic review.Adv Clin Exp Med, 2026PMID 40856087｜https://pubmed.ncbi.nlm.nih.gov/40856087/
#S06peer_reviewedIntravenous sedation and hemodynamic changes during dental implant surgery.Int J Oral Maxillofac Implants, 2011（RCT）PMID 22167437｜https://pubmed.ncbi.nlm.nih.gov/22167437/
#S07peer_reviewedRecovery Time Following Continuous Midazolam Infusion During Dental Implant Surgery: A Prospective Observational Study.Cureus, 2026PMID 41717147｜https://pubmed.ncbi.nlm.nih.gov/41717147/
#S08peer_reviewedNitrous Oxide and Oral Sedation for Managing Dental Anxiety in Children: A Systematic Review.Cureus, 2026PMID 41694161｜https://pubmed.ncbi.nlm.nih.gov/41694161/
#S09peer_reviewedInternational Guidelines on Conscious Sedation in Pediatric Dentistry: A Comparative Analysis and Evidence Mapping Study.J Clin Med, 2026PMID 41976973｜https://pubmed.ncbi.nlm.nih.gov/41976973/
#S10peer_reviewedPsychological treatment of dental anxiety among adults: a systematic review.Eur J Oral Sci, 2013PMID 23659254｜https://pubmed.ncbi.nlm.nih.gov/23659254/
#S11peer_reviewedAllergic Reactions in Dental Practice: Classification of Medicines, Mechanisms of Action, and Clinical Manifestations.Clin Rev Allergy Immunol, 2025PMID 39954171｜https://pubmed.ncbi.nlm.nih.gov/39954171/
#S12peer_reviewedLocal Anaesthetic Systemic Toxicity in Dental and Oral and Maxillofacial Surgery: Safe Dosing, Combination Agents, and Emergency Management—A Narrative Review.Dent J (Basel), 2026PMID 42505765｜https://pubmed.ncbi.nlm.nih.gov/42505765/
#S13peer_reviewedSelection of the safest local anesthetic for dental treatment in medically compromised patients: A comprehensive review.Saudi J Anaesth, 2026PMID 41710613｜https://pubmed.ncbi.nlm.nih.gov/41710613/
#S14peer_reviewedPediatric morbidity after oral surgery procedures under general anaesthesia: A systematic review.J Stomatol Oral Maxillofac Surg, 2023PMID 35961509｜https://pubmed.ncbi.nlm.nih.gov/35961509/
#S15peer_reviewedSedation versus general anaesthesia for provision of dental treatment to patients younger than 18 years.Cochrane Database Syst Rev, 2015PMID 26413895｜https://pubmed.ncbi.nlm.nih.gov/26413895/

锚定档 #01（医疗法第 63 条，geo: TW）本文未引用，理由见「编辑裁定与锚定档修正记录」第 1 条。

WRITER-ADDED SOURCES（本文自行检索并实测，未改动锚定档）

检索与实测方法：`esearch.fcgi` 取候选 PMID → `efetch.fcgi`（`rettype=abstract&retmode=xml`）批次取回原始 XML 存档 → Python ElementTree 解析 `ArticleTitle` 与 `AbstractText`（含巢状标签者以 `itertext()` 完整取出）→ 以 `span in text` 字串比对为 True 才收录。实测指令与状态码：

curl -g -s -o p21_extra.xml -w "HTTP:%{http_code}\n" \
  "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=33711405,38596946,27885969,35624907,29952645,35482282,40422600,38186148,26173721&rettype=abstract&retmode=xml"
→ HTTP:200（2026-08-06 实跑）
#basis标题出处PMID／URL补此源之理由
#W16peer_reviewedEstimated prevalence of dental fear in adults: A systematic review and meta-analysis.J Dent, 2021PMID 33711405｜https://pubmed.ncbi.nlm.nih.gov/33711405/锚定档无成人牙科恐惧之人群层级患病率，导言与第五节需要规模基准
#W17peer_reviewedAllergy to Local Anesthetics is a Rarity: Review of Diagnostics and Strategies for Clinical Management.Clin Rev Allergy Immunol, 2023PMID 35482282｜https://pubmed.ncbi.nlm.nih.gov/35482282/锚定档 #12 只有分类机制，缺「真过敏有多罕见」之量级与标准化诊断路径
#W18peer_reviewedTrue Allergies to Articaine: A 25-Year Analysis.Dent J (Basel), 2025PMID 40422600｜https://pubmed.ncbi.nlm.nih.gov/40422600/提供 25 年跨度之确认案例计数，使「罕见」有可核对之绝对数字
#W19peer_reviewedEfficacy of Hypnosis on Dental Anxiety and Phobia: A Systematic Review and Meta-Analysis.Brain Sci, 2022PMID 35624907｜https://pubmed.ncbi.nlm.nih.gov/35624907/锚定档 #11（2013）之后的成人行为处置证据，用以交叉验证并揭露异质性
#W20peer_reviewedModified dental anxiety scale: validation of the italian version.Minerva Stomatol, 2015PMID 26173721｜https://pubmed.ncbi.nlm.nih.gov/26173721/本篇范围要求「评估工具」，锚定档仅有量表名称而无工具形式与信度
#W21peer_reviewed[Standardized diagnosis results of suspected local anesthetics allergy].Zhonghua Yu Fang Yi Xue Za Zhi, 2023PMID 38186148｜https://pubmed.ncbi.nlm.nih.gov/38186148/提供「自述过敏经检测后被归为何种反应」之实际分布，支撑 2-5 节鉴别地图
#W22peer_reviewedTrue Allergy to Amide Local Anesthetics: A Review and Case Presentation.Anesth Prog, 2018PMID 29952645｜https://pubmed.ncbi.nlm.nih.gov/29952645/提供「不良反应通常是什么」之鉴别分类起句；⚠ 含 Case Reports，证据层级较低，仅用其方向陈述

逐字 span 对照（本文引用之关键语句，全部经 `span in text` 程式比对为 True）

展开 span 对照表

Fn来源#逐字 span（原文）
Fn1#S01`Unlike full anesthesia, sedation doesn't make you completely unconscious` ／ `Levels of sedation include:`（2026-08-06 重验：curl HTTP 200、90,744 bytes；同时确认原文无 `continuum` 字样，故 TL;DR 已改为分层叙述）
Fn3#S01`doesn't make you completely unconscious`
Fn4#S01`Minimal sedation. You are awake but more relaxed.`
Fn5#S01`Moderate sedation (conscious sedation)`
Fn6#S01`Deep sedation. You are very drowsy`
Fn11/Fn12#S01`You are awake during local anesthesia.`
Fn13#S01`Regional anesthesia numbs a larger area`
Fn15#S01`General anesthesia affects your whole body.`
Fn18#S01`used for a colonoscopy or dental work`
Fn101#S01`Anesthesia is generally safe.`
Fn104#S01`An allergic reaction to the anesthesia.`
Fn14#S01`You may be awake during the procedure, or you may be given sedation.`
Fn16#S01`It is used during major surgeries`
Fn17#S01`Monitored sedation makes you relaxed or sleepy.` ／ `you probably won't remember the procedure`
Fn102#S01`Heart rhythm problem (arrhythmia).`
Fn103#S01`Breathing problems.`
Fn105#S01`Temporary confusion (delirium), which can last several days in some people over the age of 60, or briefly in children after waking up from anesthesia.`
Fn106#S01`Awareness when someone is under general anesthesia. This usually means that the person hears sounds. But sometimes they can feel pain. This is rare.`
Fn107#S01`Talk to your health care provider about the benefits and risks of anesthesia.`
Fn7#W16`31 publications were deemed eligible for this systematic review.` ／ `72,577 individuals 18 years of age or older` ／ `15.3 % (95 %CI 10.2-21.2)`
Fn8#W16`12.4 % (95 %CI 9.5-15.6) and 3.3 % (95 %CI 0.9-7.1)`
Fn9#W16`31 publications were deemed eligible for this systematic review. Three studies presented low risk of bias and 28 studies presented high risk of bias`
Fn10#W16`instruments used to measure dental fear`
Fn119#W16`72,577 individuals 18 years of age or older`
Fn120#W16`among women and younger adults`
Fn22#S04`a common fear`
Fn23#S04`123 studies (19,223 participants)`
Fn24#S04`14 different formulations`
Fn31#S04`Adverse events were rare.`
Fn32#S04`the speed of onset and duration of anaesthesia`
Fn33#S04`no clinical studies met our outcome definitions`
Fn34#S04`low-quality evidence suggests that 4% articaine` ／ `was superior to 2% lidocaine`（原文成功率比较之一例；本文正文未逐一转述各药剂组合）
Fn25#S03`From 1253 identified studies, 20 met the inclusion criteria.` ／ `pediatric patients aged 3-14 years`
Fn26#S03`significantly reduced pain perception` ／ `SMD = -0.98, p = 0.011`
Fn27#S03`heart rate (HR) measurements (SMD = -0.25, p = 0.013)`
Fn28#S03`Subgroup analysis indicated significant pain reduction with CCLAD compared to conventional Inferior Alveolar Nerve Block (IANB) on WBS`
Fn29#S03`very low to moderate` ／ `The overall risk of bias was low in five studies`
Fn139#S03`demonstrating some non-significant differences`
Fn140#S03`No significant differences were observed in other pain assessment parameters`
Fn141#S03`CCLAD demonstrates potential as a non-pharmacological tool`
Fn30#S04`slightly less post-injection pain than articaine`
Fn35#S05`Out of 574 identified studies, 21 were included in the qualitative analysis (9 randomized controlled trials (RCTs), 6 case reports and 6 cohort studies), mainly focusing on children aged 6-12.`
Fn36#S05`soft tissue injuries secondary to`
Fn37#S05`Out of 574 identified studies, 21 were included in the qualitative analysis (9 randomized controlled trials (RCTs), 6 case reports and 6 cohort studies), mainly focusing on children aged 6-12.` ／ `significant pain and cooperation issues`
Fn38#S05`Effective strategies include early intervention with pharmacological and non-pharmacological approaches`
Fn39#S05`phentolamine mesylate`
Fn40#S05`non-pharmacological strategies: intraoral appliances (2 studies) and photobiomodulation (2 studies)`
Fn41#S05`The included studies varied in design, sample size and duration, limiting direct comparisons. Effect sizes and confidence intervals were inconsistently reported, and the risk of bias assessment using the Cohen's kappa test highlighted methodological heterogeneity and potential reporting bias`
Fn42#W22`a reaction to epinephrine, vasovagal syncope, or overdose toxicity`
Fn72#W22`Often, these patients may be treated under general anesthesia`
Fn44#S12`rare but potentially fatal complication`
Fn46#S12`discrepancies between guideline sources`
Fn45#S12`structured differential diagnosis to distinguish LAST from more common dental emergencies`
Fn47#S12`the additive toxicity of combined amide agents remains underappreciated`
Fn48#S12`airway support and oxygenation remain`
Fn49#S12`Patient-specific factors substantially lower the effective toxic threshold`
Fn50#S11`mediated by immunoglobulin E (IgE)`
Fn52#S11`Pseudoallergic reactions`
Fn51#S11`Delayed-type reactions mediated by sensitised T lymphocytes were also considered`
Fn53#S11`the importance of cross-reactions, in which several structurally similar molecules bind to the same IgE antibodies or T lymphocytes`
Fn54#S11`lidocaine and benzocaine`
Fn55#S11`antibiotics including penicillins and cephalosporins, latex products such as gloves and cofferdams, acrylic materials used in dental prostheses and fillings, and metal alloys containing nickel, chromium, and cobalt`
Fn2#W17`True allergic reactions involving IgE-mediated reactions and anaphylaxis are rare; they have only been identified in case reports and account for less than 1% of adverse LA reactions`
Fn56#W17`less than 1% of adverse LA reactions`
Fn57#W17`Most reactions are non-allergic`
Fn62#W17`unnecessary avoidance of LA drugs`
Fn67#W17`A detailed history of prior LA reactions`
Fn68#W17`skin prick and intradermal testing`
Fn69#W17`evaluated with patch testing`
Fn58#W18`over the last 25 years` ／ `Results: During the investigation period, 10 case reports and six case series, encompassing 29 patients with a confirmed true allergy to articaine, were identified.`
Fn59#W18`over the last 25 years` ／ `Of these patients, 20 were diagnosed with an immediate type I allergy, while 5 patients exhibited a delayed type IV allergy`
Fn60#W18`Cross-reactivity with other amide LA was reported in three cases`
Fn61#W18`articaine are exceedingly rare`
Fn43#W21`a total of 24 patients were investigated in Allergy Center of West China Hospital` ／ `Of the remaining 17 patients, 7 were considered as psychosomatic reactions (29.1%), 3 of sympathetic nervous system conditions (12.5%), 1 of spontaneous urticaria (4.2%), 2 of vasovagal syncope (8.3%), drug side effects (8.3%), skin irritation (8.3%), respectively.`
Fn63#W21`a total of 24 patients were investigated in Allergy Center of West China Hospital` ／ `on suspicion of LA allergy`
Fn64#W21`Three cases were considered LA allergy`
Fn65#W21`Three cases (12.5%) were positive in previous LA skin tests and proved to be tolerated through standardized tests`
Fn66#W21`true allergic reactions to LA are rare`
Fn70#S13`Chloroprocaine, an ester anesthetic, is recommended for patients with confirmed amide allergies.`
Fn71#S13`tailored to each patient's medical`
Fn19#S08`85-92% efficacy` ／ `rapid 30-60 s onset`
Fn73#S08`children aged 2-12 years`
Fn74#S08`70-85% success for moderate cases`
Fn79#S08`full recovery in five minutes`
Fn81#S08`Limitations include protocol variability`
Fn82#S08`5-10% paradoxical excitation`
Fn78#S08`we searched PubMed, Cochrane, and Scopus (2015-2025), including 25 studies (n≈12,500 participants)` ／ `as minimally invasive options for children aged 2-12 years`
Fn80#S08`Safety was high overall (<5% adverse events), with N₂O safer for outpatient use`
Fn83#S08`midazolam offering strong amnesia but 5-10% paradoxical excitation; hydroxyzine suited low-risk adjuncts`
Fn84#S08`cutting dropouts by 40-50%`
Fn75#S06`Two hundred fifty-five consecutive patients`
Fn85#S06`randomly assigned to receive either intravenous sedation with local anesthesia (sedation group, n = 123) or local anesthesia only (nonsedation group, n = 132)`
Fn86#S06`significantly higher in the nonsedation group`
Fn87#S06`contributed to the safety of the patient`（位于 RESULTS 段，非 CONCLUSION 段）
Fn142#S06`had a beneficial effect for hemodynamic changes`（位于 CONCLUSION 段）
Fn20#S07`the awakening time was defined as that when the BIS was` ／ `the patient's condition was assessed using the postanesthetic discharge scoring system (PADSS) and then reassessed every 20 minutes`
Fn88#S07`we evaluated American Society of Anesthesiologists (ASA) I or II patients who underwent sedation with continuous midazolam infusion during implant surgery`
Fn89#S07`Forty-six patients participated`
Fn92#S07`Forty-six patients participated` ／ `Patients under 18 years old with a history of drug allergies, obesity (body mass index of 26 kg/m2 or more), or regular use of antipsychotic, psychotropic, or hypnotic substances were excluded from the study`
Fn90#S07`If the 50 minutes of conscious sedation with midazolam were properly controlled` ／ `discharged within approximately 90-110 minutes`
Fn91#S07`within 40-60 minutes after awakening`
Fn93#S02`severe dental phobia` ／ `Special Care Dentistry (SCD) services` ／ `for adults within SCD services`
Fn94#S02`risks, implications, and costs of using GA`
Fn77#S02`expert consensus opinion`
Fn95#S02`person-centered assessment and planning`
Fn21#S02`Clinical guidelines are presented as a set of overarching principles followed by six key sections reflecting patients' pathways from referral to dental services through to their care during and after GA`
Fn76#S14`up to 91.0% of patients`
Fn96#S14`between 39.8 and 47.9%`
Fn97#S14`There is a higher prevalence for treatments in the special patient group reaching 87.7% compared to 63.3% in healthy patients`
Fn98#S14`Regarding complications, complaints occurred between 43.0 and 98.9% of cases within the first 24 hours, the main reason being pain (between 14.0% and 95.0%).`
Fn99#S14`the main reason being pain (between 14.0% and 95.0%)`
Fn100#S14`very low risk of major complications`
Fn108#S09`Twelve international guidelines` ／ `conscious sedation in pediatric dentistry`
Fn109#S09`Complete convergence`
Fn110#S09`discharge criteria (91.67%)` ／ `contraindications (83.33%)`
Fn111#S09`only 16.67% of guidelines providing`
Fn112#S09`66.67% and 50% of guidelines`
Fn113#S09`Although foundational safety principles are consistently addressed, significant heterogeneity persists in pharmacological and procedural recommendations. This variability may contribute to differences in practice and uncertainty among practitioners`
Fn114#S15`patients younger than 18 years` ／ `children and adolescents up to 18 years of age`
Fn115#S15`may lead to reduced morbidity and cost`
Fn116#S15`In our original review, we identified 16 studies for potential inclusion after searching available databases and screening titles and abstracts. After retrieving full-text studies, we found none to be eligible.`
Fn117#S15`We identified no additional studies in the updated search of July 2012. We identified two studies for possible inclusion in the updated search of July 2015; again we found these to be ineligible`
Fn118#S15`Randomized controlled studies comparing`
Fn121#S10`(DAS) or the Dental Fear Survey (DFS)`
Fn128#S10`identified 10 RCT publications`
Fn129#S10`as measured using the DAS (mean difference` ／ `-2.7), but the results were based on low`（原文于 `difference` 与 `=` 与 `-2.7` 之间为不断行空格 U+00A0，故拆为两段各自逐字比对，皆为 True）
Fn130#S10`based on low quality of evidence`
Fn131#S10`There was also some support that CBT/BT improves the patients' acceptance of dental treatment more than general anaesthesia does (low quality of evidence)`
Fn132#S10`there is evidence that behavioural interventions can help adults with dental anxiety/phobia; however, it is clear that more well-designed studies on the subject are needed`
Fn122#W20`total score ranging from 5 to 25`
Fn124#W20`Cronbach's alpha=0.92`
Fn123#W20`administered to 230 patients (98 male and 132 female patients, ages 14-88 years) undergoing oral surgery`
Fn125#W20`previous distressing experiences`
Fn126#W20`the correlation with age (p=0.01) and frequency on visiting the dentist (p=0.02) were also significant`
Fn127#W20`The patients' selection (oral surgery only) may be a limit of the study, which might not provide an estimation of anxiety prevalence in the general dental population`
Fn133#W19`19 clinical trials` ／ `Efficacy of Hypnosis on Dental Anxiety and Phobia`（原文标题）
Fn135#W19`the most evidence for the efficacy`
Fn136#W19`contrasting results for the application`
Fn134#W19`The following treatment techniques were reviewed: various forms of cognitive-behavioral therapy (CBT), relaxation training, benzodiazepine premedication, self-hypnosis by audio therapy, hypnotherapy, hypnosis, and nitrous oxide sedation`
Fn137#W19`a more consistent use of methods to examine anxiety for hypnosis research is recommended`
Fn138#W19`hypnosis can also be regarded as powerful and successful method for anxiety reduction` ／ `a small or even slightly negative effect`
Fn56（限定语）#W17`True allergic reactions involving IgE-mediated reactions and anaphylaxis are rare`

FAQ

Q1. 打麻药会痛吗？有没有办法比较不痛？
**注射疼痛是一个被测量过的变项：一篇纳入 20 篇 RCT、对象为 3–14 岁儿童的荟萃分析显示，电脑控制局部麻醉输注系统相较传统注射，在 Wong-Baker 量表上显著降低疼痛感受（SMD = -0.98, p = 0.011）[Fn26]，在心率上亦然 [Fn27]。** 要一起读的是：该研究人群为儿童 [Fn25]；在其他量表与其他注射方式上结果不一、出现部分**不具显著性**的差异 [Fn139]；在其他疼痛评估参数上**未观察到显著差异** [Fn140]；整体证据确定性介于极低至中等 [Fn29]；作者自己的结论用语是 CCLAD「展现出潜力」[Fn141]。本文不外推为成人数字，也不把它读成已确立的效果。药剂面向上，Cochrane 的中等质量证据显示：不同局部麻醉药之间的注射后疼痛差异很小，其中一种在该比较中可能略少 [Fn30]（⚠ **本文正文与 FAQ 不列药名与浓度**；用哪一种由牙医师依处置与个体状况决定，来源原文所载药名保留在事实帐供溯源），且不良事件属罕见 [Fn31]。牙科治疗的疼痛本来就是病人常见的恐惧，而它可由局部麻醉成功控制 [Fn22]。实际采用哪一种方式，须由牙医师评估。
Q1. 麻酔の注射は痛いですか。より痛くない方法はありますか。 — **注射時の痛みは測定されたことのある変数です。20 件のランダム化比較試験を組み入れ、対象が 3–14 歳の小児であるメタアナリシスは、コンピュータ制御局所麻酔注入システムが従来の注射と比較して、Wong-Baker の尺度で痛みの感じ方を有意に低下させ（SMD = -0.98, p = 0.011）[Fn26]、心拍数でも同様であったことを示しています [Fn27]。** あわせて読むべきことは次のとおりです。この研究の集団は小児であること [Fn25]、他の尺度と他の注射方法では結果が一致せず、一部に**有意でない**差が生じたこと [Fn139]、他の痛みの評価指標では**有意差が観察されなかった**こと [Fn140]、全体のエビデンスの確実性はきわめて低いものから中等度であること [Fn29]、そして著者自身の結論の言い回しは CCLAD が「可能性を示している」というものであること [Fn141]。本記事はこれを成人の数字へ外挿せず、確立した効果としても読みません。薬剤の面では、Cochrane の中等度の質のエビデンスが次を示しています。異なる局所麻酔薬の間で注射後の痛みの差はごく小さく、そのうちの一つはその比較においてやや少ないかもしれない [Fn30]（⚠ **本記事の本文と FAQ は薬剤名と濃度を挙げません**。どれを用いるかは処置と個々の状態に応じて歯科医師が決めます。出典の原文に記載された薬剤名は、トレーサビリティのために事実台帳に保持しています）。そして望ましくない事象はまれです [Fn31]。歯科治療の痛みはもともと患者によくある恐怖であり、それは局所麻酔によってうまくコントロールできます [Fn22]。実際にどの方法を採るかは、歯科医師の評価が必要です。
Q1. Does having the injection hurt? Is there any way to make it hurt less? — **Injection pain is a variable that has been measured: a meta-analysis including 20 RCTs in children aged 3–14 years shows that a computer-controlled local anaesthetic delivery system, compared with conventional injection, significantly reduced pain perception on the Wong-Baker scale (SMD = -0.98, p = 0.011) [Fn26], and likewise on heart rate [Fn27].** What has to be read alongside it: the study population was children [Fn25]; on other scales and other injection techniques the results were inconsistent, with some **non-significant** differences appearing [Fn139]; on other pain assessment parameters **no significant differences were observed** [Fn140]; the overall certainty of the evidence ranged from very low to moderate [Fn29]; and the authors' own concluding wording is that CCLAD “demonstrates potential” [Fn141]. This article does not extrapolate it into a figure for adults, and does not read it as an established effect. On the agent side, moderate-quality evidence from Cochrane shows that the difference in post-injection pain between different local anaesthetics is very small, and that one of them may be slightly less in that comparison [Fn30] (⚠ **neither the main text nor the FAQ of this article lists drug names or concentrations**; which one is used is decided by the dentist according to the procedure and the individual's circumstances, and the drug names given in the source are retained in the fact ledger for traceability), and that adverse events were rare [Fn31]. Pain in dental treatment is in any case a common fear among patients, and it can be successfully controlled by local anaesthesia [Fn22]. Which approach is actually adopted has to be assessed by the dentist.
Q2. 麻药多久退？还没退的时候要注意什么？
**诚实的答案是：在系统综述层级上，这个问题目前没有统合出来的通用数字。** Cochrane 的主要目标之一即包含比较起效速度与持续时间 [Fn32]，但结果是没有临床研究符合其结果定义 [Fn33]。局部麻醉本身涵盖 14 种不同配方 [Fn24]，所以时间不会是一个常数。真正需要注意的是麻退前的空窗期：一篇纳入 21 篇研究、以 6–12 岁儿童为主的系统综述指出，局部麻醉后续发的软组织创伤可造成显著疼痛与合作问题 [Fn37]，有效策略包含以药物与非药物途径及早介入 [Fn38]。**本文不提供任何操作或用药指示**；当次该注意什么，请由施打的牙医师交代。
Q2. 麻酔はどれくらいで切れますか。まだ切れていないときは何に注意すればよいですか。 — **誠実な答えは次のとおりです。システマティックレビューの層において、この問いには現時点で統合された共通の数字がありません。** Cochrane の主要な目的の一つには効き始めの速さと持続時間の比較が含まれていましたが [Fn32]、結果はそのアウトカムの定義を満たす臨床研究が一件もなかったというものでした [Fn33]。局所麻酔そのものが 14 種類の異なる製剤を含むため [Fn24]、時間は一つの定数にはなりません。本当に注意すべきなのは麻酔が切れる前の空白の時間です。21 件の研究を組み入れ、6–12 歳の小児を主とするシステマティックレビューは、局所麻酔の後に続発する軟組織の損傷が著しい痛みと協力の問題を引き起こしうると指摘しており [Fn37]、有効な方策には薬理学的および非薬理学的な手段による早期の介入が含まれます [Fn38]。**本記事はいかなる操作の指示も薬の使用の指示も提供しません**。その回に何に注意すべきかは、施行した歯科医師から説明を受けてください。
Q2. How long until the anaesthetic wears off? What should I watch for while it has not yet worn off? — **The honest answer is that at the level of systematic review there is at present no pooled general figure for this question.** One of Cochrane's primary objectives included comparing the speed of onset and duration [Fn32], but the result was that no clinical studies met its outcome definitions [Fn33]. Local anaesthesia itself covers 14 different formulations [Fn24], so the timing will not be a constant. What genuinely needs watching is the window before the anaesthetic wears off: a systematic review including 21 studies, mainly in children aged 6–12 years, notes that soft-tissue injuries secondary to local anaesthesia can cause significant pain and cooperation issues [Fn37], and that effective strategies include early intervention with pharmacological and non-pharmacological approaches [Fn38]. **This article provides no procedural instruction and no medication instruction**; what to watch for on the day is to be explained by the dentist who gives the injection.
Q3. 怕看牙可以「睡着做」吗？笑气、舒眠、全身麻醉差在哪？
**「睡着」在专业上不是一个开关，而是分层的：镇静不会使人完全失去意识、恢复较快 [Fn3]，且分为轻度、中度（清醒镇静）与深度三段 [Fn4][Fn5][Fn6]；全身麻醉才是影响全身、如同深睡的层级 [Fn15]。** 各段的证据厚度不同：笑气在 2–12 岁儿童的轻度焦虑人群效果为 85–92%、并发症低于 5%、起效 30–60 秒 [Fn19][Fn73]，五分钟内完全恢复 [Fn79]；口服镇静对 2–12 岁儿童的中度病例为 70–85% [Fn73][Fn74]；静脉镇静在 255 人的种植牙 RCT 中被测得对血液动力学变化有正面效果 [Fn75][Fn142]；全身麻醉则由英国身心障碍牙科学会指引在**特殊照护牙科服务**的脉络下记载，可能被需要以让有重度学习障碍或重度看牙恐惧者接受广泛牙科治疗 [Fn93]，但该指引自陈可用证据稀少 [Fn77]。**另外要知道的是**：Cochrane 针对**未满 18 岁病人**寻找「镇静 vs 全身麻醉」的随机对照研究，三轮检索后没有一篇符合资格 [Fn114][Fn116][Fn117]，该人群因此没有头对头实证比较，作者的结论是仍需要这类研究 [Fn118]；**成人人群不在该回顾的检索范围内** [Fn114]，这份空回顾不能被读成对成人的任何结论。非药物路径同样存在：CBT/BT 可显著降低成人牙科焦虑（DAS 平均差 -2.7，低质量证据）[Fn129][Fn130]。选哪一条，须由牙医师评估。
Q3. 歯科が怖いのですが「眠っている間に」できますか。笑気、鎮静、全身麻酔はどう違いますか。 — **「眠る」は専門の上ではスイッチではなく、層に分かれています。鎮静は意識を完全に失わせるものではなく、回復もより速く [Fn3]、軽度・中等度（意識下鎮静）・深度の三段階に分かれます [Fn4][Fn5][Fn6]。全身麻酔こそが全身に作用し、深い眠りのように感じられる層です [Fn15]。** 各段階のエビデンスの厚みは異なります。笑気は 2–12 歳の小児の軽度の不安の集団で効果が 85–92%、合併症は 5% 未満、効き始めは 30–60 秒 [Fn19][Fn73]、5 分間以内に完全に回復するとされます [Fn79]。経口鎮静は 2–12 歳の小児の中等度の症例で 70–85% [Fn73][Fn74]。静脈内鎮静は 255 名のインプラント手術の RCT で血行動態の変化に有益な効果が測定されています [Fn75][Fn142]。全身麻酔は英国障害者口腔保健学会のガイドラインが**スペシャルケア歯科のサービス**の文脈において、重度の学習障害または重度の歯科恐怖症のある人が広範な歯科治療を受けられるようにするために必要となりうると記載していますが [Fn93]、同ガイドライン自身が利用できるエビデンスは乏しいと述べています [Fn77]。**もう一つ知っておくべきことは次のとおりです**：Cochrane は**18 歳未満の患者**について「鎮静 vs 全身麻酔」のランダム化比較研究を探し、三度の検索の後も一件も適格ではありませんでした [Fn114][Fn116][Fn117]。この集団にはそのため直接比較の実証がなく、著者の結論はこの種の研究がなお必要だというものです [Fn118]。**成人の集団はそのレビューの検索の範囲に入っておらず** [Fn114]、この空のレビューを成人についてのいかなる結論としても読むことはできません。非薬理学的な経路も存在します。CBT/BT は成人の歯科不安を有意に低下させます（DAS 平均差 -2.7、質の低いエビデンス）[Fn129][Fn130]。どれを選ぶかは、歯科医師の評価が必要です。
Q3. If I am afraid of the dentist, can I “have it done asleep”? What is the difference between nitrous oxide, sedation and general anaesthesia? — **Professionally, “asleep” is not a switch but a set of layers: sedation does not make a person completely unconscious and recovery is quicker [Fn3], and it is divided into the three bands of minimal, moderate (conscious sedation) and deep [Fn4][Fn5][Fn6]; general anaesthesia is the level that affects the whole body and is like a deep sleep [Fn15].** The thickness of the evidence differs from band to band: in the mild-anxiety population of children aged 2–12 years, nitrous oxide has an efficacy of 85–92%, complications under 5% and an onset of 30–60 s [Fn19][Fn73], with full recovery in five minutes [Fn79]; oral sedation is 70–85% for moderate cases in children aged 2–12 years [Fn73][Fn74]; intravenous sedation was measured in a 255-patient implant RCT as having a beneficial effect for haemodynamic changes [Fn75][Fn142]; and general anaesthesia is recorded by the British Society for Disability and Oral Health guideline, in the context of **Special Care Dentistry services**, as possibly being needed to enable people with severe learning disability or severe dental phobia to receive extensive dental treatment [Fn93], although that guideline states that the available evidence is scarce [Fn77]. **What also has to be known**: Cochrane's search for randomised controlled studies of “sedation vs general anaesthesia” in **patients younger than 18 years** found, after three rounds of searching, that not one was eligible [Fn114][Fn116][Fn117]; that population therefore has no head-to-head empirical comparison, and the authors' conclusion is that such studies are still needed [Fn118]; **the adult population was not within the search scope of that review** [Fn114], and this empty review cannot be read as any conclusion about adults. The non-pharmacological pathway exists just as much: CBT/BT can significantly reduce dental anxiety in adults (DAS mean difference -2.7, low quality of evidence) [Fn129][Fn130]. Which one to choose has to be assessed by the dentist.

来源锚定

引用本文

km 編輯部・《牙科麻醉、镇静与看牙恐惧全指南：从局部麻醉原理、镇静光谱到焦虑评估的领域地图｜證據鏈》・IDAEO 知識庫・2026-08-13・https://km.idaeo.ai/post/reports/dental-pillar-anesthesia-anxiety-evidence

相关文章

更新 2026-08-13T14:17:27.544Z · server-rendered · four-language · IDAEO 知識庫